Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study
- 1 December 1995
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 13 (3) , 285-294
- https://doi.org/10.1016/0169-5002(95)00501-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- High-Dose Cisplatin with Dipyridamole in Advanced Non-Small Cell Lung CancerAmerican Journal of Clinical Oncology, 1995
- A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancerLung Cancer, 1994
- Five-Year Survival After Hyperfractionated Radiation Therapy for Non-Small-Cell Carcinoma of the Lung (NSCCL)American Journal of Clinical Oncology, 1991
- Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group BCancer, 1991
- Is chemotherapy for metastatic non-small cell lung cancer "worth it"?Journal of Clinical Oncology, 1990
- A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer GroupCancer Chemotherapy and Pharmacology, 1990
- High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology GroupCancer Chemotherapy and Pharmacology, 1990
- A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.Journal of Clinical Oncology, 1986
- Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.Journal of Clinical Oncology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958